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Background: The clustering of metabolic abnormalities defined as metabolic syndrome is now both a public
health and a clinical problem .While interest in herbal medicine has greatly increased, lack of human evidence to
support efficacies shown in animals does exist. This clinical trial study designed to investigate whether herbal
medicine, Anethum graveolens (dill) extract, could improve metabolic components in patients with metabolic
syndrome.
Methods: A double-blind, randomized, placebo-controlled trial using a parallel design was conducted. 24 subjects
who had metabolic syndrome diagnostic criteria (update of ATP III) were randomly assigned to either dill extract
(n = 12) or placebo (n = 12) for 3 months.
Results: Across lipid component of metabolic syndrome, no significant differences in triglyceride (TG) concentration
and high density lipoprotein cholesterol were seen between the two groups. However TG improved significantly
from baseline (257.0 vs. 201.5p = 0.01) with dill treatment but such a significant effect was not observed in placebo
group. Moreover, no significant differences in waist circumference, blood pressure and fasting blood sugar were
seen between two groups after 3 months follow up period.
Conclusion: In this small clinical trial in patients with metabolic syndrome, 12 weeks of dill extract treatment had a
beneficial effect in terms of reducing TG from baseline. However dill treatment was not associated with a significant
improvement in metabolic syndrome related markers compared to control group. Larger studies might be required
to prove the efficacy and safety of long-term administration of dill to resolve metabolic syndrome components.
Keywords: Anethum graveolens, Dill, Metabolic syndrome, Hyperlipidemia, Clinical trial, Abdominal obesityIntroduction
The clustering of metabolic abnormalities defined as
metabolic syndrome does occur in one quarter of the
world’s adults. People with metabolic syndrome are three
times as likely to have a heart attack or stroke compared
with people without the syndrome and have a five-fold
greater risk of developing type 2 diabetes [1].
While metabolic syndrome causes the two global epi-
demics of type 2 diabetes and cardiovascular disease* Correspondence: sh_hasani@sina.tums.ac.ir
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reproduction in any medium, provided the or(CVD), it overpowers any effort to identify and treat
those individuals with metabolic syndrome early, so that
new and effective treatment methods may prevent the
development of diabetes and/or CVD [1].
Although, complementary and alternative therapies
have long been used in the Eastern world, interest to
herbal medicine along with the isolation and standard-
ization of herbal constituents has greatly increased
worldwide and would open a new approach for novel
therapeutic and more effective agents to treat or prevent
diseases such as diabetes mellitus [2].
Anethum graveolens L. known as dill is a sparse look-
ing plant with feathery leaves and tiny yellow flowersal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.darujps.com/content/20/1/47growing in the Mediterranean region, Europe, central
and southern Asia and is widely cultured in south east-
ern region of Iran [3]. The metabolic syndrome is a
complex of interrelated risk factors for CVD and dia-
betes [4]. In an urban population of Tehran MONICA
project using the Adult Treatment Panel III (ATPIII) cri-
teria showed that the crude prevalence rate of the meta-
bolic syndrome was 29.9 %, meaning that more than one
fourth of the population are at risk of CVD and diabetes
[5]. As a result, the metabolic syndrome is now both a
public health and a clinical problem urging investiga-
tions on new methods for its treatment.
While the use of herbal medicine is gaining consider-
able recognition and popularity worldwide, a lack of
medical evidence to support its therapeutic efficacy does
exist and a few herbs have been clinically studied [6]. As
a folk remedy Anethum graveolens or dill is considered
for some gastrointestinal ailments such as flatulence, in-
digestion, stomachache [7] and in traditional Iranian
medicine (TIM) has been used as carminative, antispas-
modic, sedative, lactagogue, diuretic and for hyperlipid-
emia [8].
Pharmacological effects of dill such as anti-inflammatory
[9], antimicrobial [10-12] or antibacterial [13,14] , antihy-
perlipidaemic , antihypercholesterolaemic [15-17] , anti-
oxidative and hypoglycemic [16-18] activities have been
shown. To date, the role of dill extract in the improve-
ment of metabolic syndrome parameters has not been
investigated. However there have been two human ran-
domized clinical trials evaluating the lipid lowering effect
of dill extract. Unlike most studies carried on animals, a
few human studies showed this herbal treatment has no
significant reducing effect in hyperlipidemic patients
[19,20].
It is worth mentioning that in human studies, hyper-
lipidemic patients have received a patented compound
named Anthum which consists mostly of Anethum
graveolens (68%) and less of Cichorium intybus, Fumaria
parviflora and Citrus sp [21].
Due to the not existence enough human studies, we
designed a double blind randomized, placebo-controlled
trial to evaluate whether purred extracted dill could
safely improve metabolic parameters in patients with
metabolic syndrome.
Material and methods
Participants
A total of 110 ambulatory, community-dwelling Tehra-
nian men and women volunteers between the ages of 18
and 50 were considered for initial screening. They were
invited through the flyers distributed throughout the
Shariati Hospital wards particular places where visible to
public from January to December 2009. All volunteers
were interviewed by attending physician regarding to lifestyle, present and past medical history and using any
medication or supplements.
If volunteers met initial eligibility criteria through the
first interview, underwent physical exams and primary
laboratory test to participate in this study. Metabolic
syndrome were defined based on the AHA/NHLBI up-
date of Adult Treatment Panel (ATPIII) criteria [22]
consisting of
1) Elevated waist circumference >88 cm (female),
>102 cm (male)
2) Reduced HDL cholesterol < 50 mg/dl (female),
<40 mg/dl (male)
3) Elevated triglyceride ≥ 150 mg/dl
4) Elevated blood pressure ≥130/85 mmHg
5) Elevated fasting blood glucose ≥ 100 mg/dl
Exclusion criteria included any history of clinical car-
diovascular disease (myocardial infarction, angina,
stroke, heart failure), diabetes mellitus, systemic, neuro-
logic, psychiatric and endocrine diseases, liver function
test abnormalities (aspartate aminotransferase or alanine
aminotransferase levels > 3 times upper limit of normal),
renal insufficiency (creatinine levels > 2.5 mg/dl) women
who were pregnant, breastfed or have a pregnancy plan
for the next 6 months and use of any medications, diet-
ary supplements and herbals except of analgesics within
30 days prior to screening. Participants with a diagnosis
of hypothyroidism could be included only if their level
of TSH was within the normal range while they were re-
ceiving at least 3 months of a stable dose of thyroid re-
placement. Finally a total of 24 patients who had ≥3 of
the metabolic syndrome diagnostic criteria and other eli-
gibility criteria entered the study. Eighty six of partici-
pants were excluded because of the following reasons; in
first lab results we noticed that many participants didn’t
fulfill the metabolic syndrome criteria. Some of them
were on diet and less inclined to participate in wash out
period and a few were newly diagnosed of type 2
diabetes.Study protocol
A double-blind, randomized, placebo-controlled trial using
a parallel design with a 3-month follow up period, was
established. A permuted-balanced-block randomization
was employed to generate the random assignment of 24
subjects by order of entry into two different treatment
groups. Each group received either Anethum graveolens ex-
tract (AGE) or placebo, one pill (600 mg) per day for
3 months. Subjects were visited during four time’s period:
basal, first month, second month and third month.
Twelve- hour fasting blood samples were obtained before
each visiting session. During each visit anthropometric
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asked questions about unexpected adverse events.
Body weight was assessed with a standard scale while
they were lightly dressed and barefoot. Height was mea-
sured using a wall-mounted stadiometer. The body mass
index (BMI) was measured by dividing the weight (kg) to
height (m2). Waist circumference (WC cm) defined as
the minimal abdominal circumference between the xiph-
oid process and iliac crest. Left hand blood pressure was
measured by using standard mercury sphygmomanom-
eter in the sitting position. The blood pressure values
were confirmed by a second measurement after 5
minutes.
All study personnel were blinded to treatment assign-
ment. All participants were told to maintain their usual
dietary habits (diet stability was assessed and verified by
analyzing all dietary recalls taken during each study visit
by a registered dietitian). Adherence to study medication
was assessed by pill count at each visit. Protocol of the
study has been approved (Code: E-0046) by both the in-
stitutional review board and ethics committee of endo-
crinology and metabolic research institute (EMRI) of
Tehran University of Medical Sciences. After giving
required information about the details of the study pro-
gram, all participants assigned written consent form.
Preparation of dill extract
Dried aerial parts of Anethum graveolens including
leaves and steams were purchased locally from herbal
markets. The plant was identified by herbaria’s expert of
pharmacology department of Tehran University of Med-
ical Sciences (TUMS). The hydro alcoholic extract of
dried dill was prepared in the food and drug research la-
boratory of EMRI using following procedure. For the
preparation of the hydro alcoholic extract, 100 gram of
the dried grounded plant was suspended in 400 mL
double distilled water- ethanol (2:1; v/v). The extract
was filtered and the filtrate was evaporated to dryness
with a rotatory vacuum evaporator. Then the dried pow-
der (600 mg) was put into empty gelatin capsules by
pharmaceutical company. More over the other gelatin
capsule containing rice starch powder in the same color
employed as a placebo. The toxicity assessment of
hydroalcoholic extract of oral Anethum graveolens in
animal was evaluated by Arbabi et al [23]. According to
this study doses less than 50 mg/kg could be considered
as no observable adverse effect level (NOAEL) and could
be used in the future clinical investigations.
Assessment of adverse events
After initiation of the study, drug-related adverse effects
were assessed by using questionnaire, physical examin-
ation and laboratory tests. The physician filled out a
copy of the healthy questionnaire based on interviewwhich was about changes in their general health since
their last visit and physical examination of the patient.
Besides vital sign monitoring (temperature, blood pres-
sure, pulse rate) cardio respiratory and abdominal exam-
ination were also performed per visiting session (in each
visit). Potentially adverse reaction on kidney and liver
function were evaluated by measuring serum creatinine,
electrolytes, liver enzyme, bilirubin (total and direct) and
albumin at baseline and each visit. Drug related hema-
tologic reaction was assessed by measuring the serum
levels of all blood cells. Shifts from normal range and
clinically and statistically significant deviation from base-
line values of laboratory parameters were recorded as
adverse events at each visit.
Biochemical analysis
White and red blood cell counts and hemoglobin levels
were measured using a Multi hematologic Analysis Sys-
tem (Sismex, Japan). The following biochemical para-
meters were measured in the EMRC blood analysis
laboratory using an automatic analysis system (Autoana-
lyzer; Hitachi Ltd, Tokyo, Japan) with enzymatic kits
(Pars Azmoon, Iran): serum triglyceride (TG mg/dl),
total cholesterol (TC mg/dl), high-density lipoprotein
cholesterol(HDL-C mg/dl), low-density lipoprotein chol-
esterol (LDL-C mg/dl), fasting blood glucose (FBS mg/
dl), alkaline phosphatase (ALP IU/L), alanine aminotran-
ferease (ALT IU/L) and aspartate aminotransferase (AST
IU/L), creatinine (mg/dl), blood urea nitrogen (mg/dl)
and albumin (g/dl). All inter-assay calculated coefficients
of variation were within the normal range of enzymatic
kits data sheets.
Statistical analysis
Results are expressed as means ± SD. Significance of dif-
ferences was evaluated using the SPSS statistical program
package (SPSS; 16, Inc, USA) and defined at 0.05 level of
confidence. Normality assumption of variables was
assessed by Kolmogorov-Smirnov test and then the com-
parison between groups mean differences at baseline and
each month was performed by student's t test. Within
groups mean changes from baseline to final values at 4, 8
and 12 weeks in component of metabolic syndrome and
other variable were analyzed by using paired t test.
Results
Over an 11-month period, 110 healthy individuals were
screened for the study, and 24 were eligible based on
entry criteria. 20 of 24 participants completed all study-
related visits. Thus the twelve weeks data analysis was
performed in 20 subjects who completed the study (10
subjects in each group).Patient recruitment and screen-
ing process for trial is shown in Figure 1.
110 adults assessed for eligibility 
86 excluded
24 randomized 
12 assigned to 
receive dill 
extract
12 assigned to 
receive placebo 
12 included in 
8 weeks data 
analysis 
12 included in 
8 weeks data 
analysis 
2 lost to follow 
up: 1 withdrawn 
1 fasting month
2 lost to follow 
up: 1 relapse of 
back pain 1 fasting
month  
10 included in 
12 weeks data 
analysis  
10 included in 
12 weeks data 
analysis 
Figure 1 Flow of the trial.
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study subjects in the two groups were similar and there
were no significant differences between the two groups
for metabolic syndrome parameters including WC,
HDL-C, BP, FBS and TG (Table 1).
Changes in metabolic syndrome parameters after 8 weeks
The 8 weeks data analysis was performed for 24 partici-
pants. Compared to baseline values no significant
changes in metabolic syndrome components were found
after 8 weeks in dill treatment group (Table 2). More-
over blood analysis showed no significant changes in
markers for kidney and liver function as determined by
serum creatinine and liver enzymes. In addition, placebo
using for 8 weeks didn’t significantly affect metabolic
syndrome parameters and mentioned markers.
Changes in metabolic markers after 12 weeks
Regarding to vital signs (pulse rate, respiratory rate) and
physical exams, both groups didn’t show any significant
changes compared to baseline (Data not shown). Therewas no significant change in Body Mass Index (BMI)
and WC and blood pressure at the end of 12 weeks of
treatment and two groups were not different from each
other. In addition there were no statistically significant
changes in dietary intakes (calories) between baseline
and month 3 for each of the treatment groups as
assessed by analyzing dietary recalls taken at each study
visit, suggesting that diet remained stable during the
treatment period in both groups. After 3 months of dill
extract or placebo consumption, mean fasting blood glu-
cose didn’t differ between two groups. Across lipid com-
ponent of metabolic syndrome, no significant differences
in fasting TG concentration and HDL-C were seen be-
tween the two groups. However TG improved signifi-
cantly from baseline (257.0 vs. 201.5p = 0.01) with dill
treatment but such a significant effect was not observed
in placebo group. Moreover LDL-C was also not signifi-
cantly different between the two groups (Table 3).
Safety and tolerability
Safety was assessed by physical examination, evaluation
of vital signs, and various laboratory measurements.
There were no changes in clinical laboratory assessment
including liver enzymes, total bilirubin, albumin, creatin-
ine, and electrolytes among any of the treatment groups
during follow up period. In addition, no apparent differ-
ences were observed in the safety parameters including
vital signs, results of physical examination and
hematologic tests in both groups. The only changes in
hematologic tests were a significant trend for WBC to
decrease in placebo group after 12 weeks, compared to
baseline. Moreover a significant difference was observed
in platelet level in dill group compared to placebo. In
general both capsules were well tolerated with only few
subjects had complained about the smell of the dill cap-
sules, but they had continued the study to the end.
Discussion
The present double blind randomized controlled trial
examined whether the AGE or dill extract is capable to
improve the lipid profile and other metabolic syndrome
determinants. To our knowledge, this is the first study
to demonstrate an effect for a pure dill extract on sub-
jects with metabolic syndrome. Lipid disturbance is a
prominent feature of metabolic syndrome. Although
many studies have reported beneficial effect of dill treat-
ment on lipid profile but most of these investigations
have been conducted on animals [15-17,24]. The find-
ings of the present study showed that dill extract
resulted in significant reduction in TG levels from base-
line to week 12. However serum TG was not signifi-
cantly different in dill group compared with placebo.
The result of our study in agreement with the con-
clusion of previous human studies reporting dill
Table 1 Baseline characteristics of Study Participants
Variables Placebo (n = 12) Dill extract (n = 12) P value
Age(yr) 36.8(9.6) 38.2(8.2) 0.7
Sex Male n (%) 7(58.3) 6(50.0) 0.5
Weight(kg) 97.2(17.5) 103.1(26) 0.5
BMI(kg/m2) 37.8(7.4) 36.6(8.1) 0.7
WC (cm) 107.8(13.7) 110.8(14.3) 0.6
SBP (mm Hg) 121.0(12.9) 121.6(17.7) 0.9
DBP (mm Hg) 84.0(9.4) 81.3(10.3) 0.5
WBC 6.9(2.0) 6.2(1.69) 0.3
PLT 278.6(93.4) 220.2(77.1) 0.1
FBS (mg/dl) 101.0(11.7) 105.6(12.3) 0.3
Serum creatinine (mg/dl) 0.9(0.1) 0.9(0.21) 0.4
TG(mg/dl) 252.8(111.7) 257.0(124.5) 0.8
TC(mg/dl) 215.7(23.01) 210.9(24.0) 0.6
LDL-C(mg/dl) 122.1(18.5) 116.9(17.3) 0.4
HDL-C(mg/dl) 37.9(4.0) 39.4(6.8) 0.5
AST (IU/L) 28.0(13.09) 21.00(7.23) 0.1
ALT (IU/L) 39.6(31.6) 22.27(14.5) 0.1
ALP(IU/L) 190.0(56.3) 187.8(56.9) 0.9
Value are presented as mean(SD).BMI, body mass index ; WC, waist circumference; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, White blood
cells; FBS, fasting blood sugar; TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate transaminase; ALT,
alanine transaminase; ALP, alkaline phosphatase.
Mansouri et al. DARU Journal of Pharmaceutical Sciences 2012, 20:47 Page 5 of 7
http://www.darujps.com/content/20/1/47consumption has no effect on lipid profile in hyperlipid-
emic patients [19,20]. But these results are in contrast to
what has previously been reported by animal studies
[15-17,24].The discrepancy in results may be attributed
to several factors including differences in prescribedTable 2 Changes in metabolic syndrome parameters and othe
Variable Placebo Group (n = 12)
After 8 weeks Mean change P
Weight(kg) 96.3(20.1) −0.9 0.1
BMI(kg/m2) 35.2(6.9) −2.6 0.2
WC (cm) 107.7(13.6) −0.1 0.7
SBP (mm Hg) 117.7 (17.9) −3.3 0.5
DBP (mm Hg) 80.5 (9.9) −3.5 0.7
WBC 6.8(2.2) −0.1 0.8
PLT 268.4(75.8) −10.2 0.9
FBS (mg/dl) 95.7(12.1) −5.3 0.3
Serum creatinine (mg/dl) 0.9(0.2) 0.0 0.6
TG(mg/dl) 230.1(57.9) −22.7 0.1
TC(mg/dl) 215.3(19.1) −0.4 0.5
LDL- C(mg/dl) 122.5(12.9) 0.4 0.7
HDL-C(mg/dl) 39.8(8.2) 1.9 0.4
AST (IU/L) 20.2(6.9) −7.8 0.2
ALT (IU/L) 26.8(19.5) −12.8 0.2
ALP (IU/L) 164.8(40.9) −25.2 0.1
Values are expressed as mean (SD). BMI, body mass index ;WC, waist circumference
cells; FBS, fasting blood sugar; TG, triglyceride; TC, total cholesterol; HDL, high-dens
alanine transaminase; ALP, alkaline phosphatase.dosage, kind of dill consumption, non standardization of
the dill manufacturing method and variation in the ana-
lysis method. One of the main differences between ani-
mal and human studies was prescribed dosage .
Considering weight factor the prescribed dosage inr variables from baseline to 8–week follow-up
Dill Extract Group (n= 12) Dill vs placebo
After 8 weeks Mean change p P
100.9(27.0) −2.2 0.1 0.6
36.1(7.5) −0.5 0.2 0.9
109.0(14.8) −1.8 0.7 0.8
116.8(14.8) −4.8 0.5 0.6
77.8(12.0) −3.5 0.2 0.8
7.0(1.4) 0.8 0.8 0.8
250.9(65.4) 30.7 0.9 0.6
105.8(17.6) 0.2 0.3 0.1
0.9(0.1) −0.02 0.6 0.6
232.3(100.6) −24.7 0.1 0.9
206.6(28.2) −4.3 0.8 0.3
113.1(14.7) −3.6 0.4 0.1
38.5(6.9) −0.7 0.5 0.7
20.7(8.9) −0.3 0.2 0.8
28.0(23.1) 6.7 0.2 0.5
191.57(54.5) 3.77 0.1 0.4
; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, White blood
ity lipoprotein; LDL, low-density lipoprotein; AST, aspartate transaminase; ALT,
Table 3 Changes in metabolic syndrome parameters from baseline to 12-weeks follow-up
Variable Placebo Group (n =10) Dill Extract Group (n = 10) Dill vs placebo
After 12 weeks Mean change P After 12 weeks Mean change p P
Weight(kg) 101.4(17.7) 4.2 0.2 100.7(28.9) −2.4 0.7 0.9
BMI(kg/m2) 36.9(7.4) −0.9 0.2 35.8(8.1) −0.8 0.8 0.7
WC (cm) 111.4(13.5) 3.6 0.8 108.8(15.2) −2 0.7 0.7
SBP (mm Hg) 113.4(11.7) −7.6 0.2 116.0(18.9) −5.6 0.3 0.7
DBP (mm Hg) 76.8(7.03) −7.2 0.2 77.8(11.7) −3.5 0.1 0.8
WBC 5.7(1) −1.2 0.04 6.8(1.1)) 0.6 0.4 0.3
PLT 289(59.9) 10.4 0.7 210.9(37.3) −9.3 0.7 0.004
FBS (mg/dl) 100(15.8) −1.3 0.6 103.0(11.9) −2.6 0.2 0.6
Serum creatinine (mg/dl) 1.0(0.1) 0.1 0.6 0.93(0.2) 0.03 0.7 0.8
TG(mg/dl) 197.1(86.1) −55.7 0.2 201.5(115.5) −55.44 <0.01 0.9
TC (mg/dl) 209.1(23.8) −6.6 0.3 196.7(26.9) −14.2 0.2 0.3
LDL-C (mg/dl) 124.4(15.8) 2.3 0.8 109.2(16.1) −6.7 0.6 0.1
HDL-C (mg/dl) 39.0(4.7) 1.1 0.9 36.1(7.3) −3.3 0.2 0.3
AST (IU/L) 26.6(9.5) −1.4 0.3 23.9(11.3) 2.9 0.3 0.1
ALT (IU/L) 37.7(13.3) −1.9 0.3 27.9(27.0) 5.6 0.4 0.9
ALP (IU/L) 179.6(56.0) −10.4 0.2 175.2(49.3) −12.6 <0.01 0.5
Value are presented as mean(SD).BMI, body mass index; WC, waist circumference ; SBP, systolic blood pressure; DBP, diastolic blood pressure; WBC, White blood
cells; FBS, fasting blood sugar;TG, triglyceride; TC, total cholesterol; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate transaminase; ALT,
alanine transaminase;ALP, alkaline phosphatase.
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human studies. The results of animal studies indicate
that AGE in a dose dependent manner reduces lipid pro-
file components. It seems that additional human trials
are needed to clarify the amount of dill to produce clin-
ically meaningful effect on metabolic markers without
inducing the serious adverse events. Another difference
is that we used a hydro alcoholic pure extract of dill,
however, in those former studies combination prepar-
ation of several herbs with 68 % of dill, patented as
“Anethum” was investigated [21]. It is shown that plant
density and harvest timing influences dill oil compos-
ition in a complimentary manner[25]. Moreover the lack
of standardization in herbal preparation may affect the
content of the active ingredient and its efficacy [26].
A part from those mentioned, we suggest that different
analysis method could be another explanation for the
conflicting results between studies. Some studies
reported significant decrease in lipid profile in response
to dill consuming used only within group’s analysis.
Comparing baseline and after dill intervention we also
found that TG level significantly decreased in dill group.
While comparing after treatment TG measures between
dill and placebo group we didn’t find any significant dif-
ferences (Table 3). It also seems appropriate to consider
that lipid lowering effect of dill may be due to its ability
to interact with or potentiate the action of various anti-
hyperlipidemic agents. In the other hand lipid reducing
effect of dill might appear more efficient in combinationwith diet or other hypolipidemic agents .Thus more in-
vestigation are needed in this regard.
Abnormality in blood pressure and fasting blood sugar
are other important features of metabolic syndrome. In
the present study neither blood pressure measures nor
fasting blood sugar were affected by dill treatment.
Regarding blood pressure no previous studies have
attempted to describe blood pressure response to dill
consumption. It is worth mentioning that the mean
blood pressure in our population was not high. It seems
that the effect of dill treatment would be more evident
and better evaluated if the patients had high initial blood
pressure. In general, dill extract was well tolerated and
no adverse reaction was observed. We have no explan-
ation for mild decrease in WBC in placebo group and
platelet differences between two groups. However these
changes were in the normal range and were not clinic-
ally significant. The lack of finding efficient effect of dill
extract on the feature of metabolic syndrome in this
study might be partly related to small population avail-
able for this study.
The strict inclusion criteria and consequently carefully
selected cases restricted our ability to find larger sample
size. Indeed we excluded the patients with concomitant
medication, to assess the pure effect of dill extract and to
prevent interaction effect of other treatments. These two
although are strength points of this study but limit the
ability to provide adequate statistical power for document-
ing the results. The shortness of the length study period
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the variation of the components contributing the meta-
bolic syndrome diagnosis could be another limitation. In
other words, we considered at least three criteria for the
metabolic syndrome definition to include patients in this
study, but these criteria were different from one to other.
Conclusion
In this small clinical trial in patients with metabolic syn-
drome, 12 weeks of dill extract treatment had a beneficial
effect in terms of reducing TG from baseline. However dill
treatment was not associated with a significant improve-
ment in metabolic syndrome related markers compared to
control group. Larger studies might be required to prove
the efficacy and safety of long-term administration of dill
extract to resolve metabolic syndrome components.
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